Longevity Startups

The Longevity Science Foundation funds scientific research to address the biological drivers of women's health disparities, particularly ovarian aging and menopause. The foundation is raising capital to simultaneously advance measurement technologies, biological understanding, and early-stage interventions targeting reproductive aging.

1 investor

Longevity Health provides health insurance plans focused on optimizing quality of life for people in long-term care through value-based, personalized solutions addressing physical, mental, emotional, and social well-being.

1 investor

Longevity Group, the flagship division of Deep Knowledge Group, operates an integrated longevity platform combining a digital member club, a cluster of real-world longevity facilities in Dubai, a healthspan–wealthspan marketplace with a banking card, and blueprint-to-implementation software (LBams and API-AMS) for configuring and deploying longevity clinics and facilities. It serves individuals, clinics, wellness operators and real-estate developers, with a flagship focus on Dubai and the broader UAE/Gulf market and white-label replication elsewhere.

1 investor

Longevity AI offers Florence AI, a clinical tool that analyzes patient data across cardiovascular, metabolic, cognitive, and immune systems, tracks patient trajectories between visits, and drafts clinical summaries, SOAP notes, and personalized care plans. It is built for clinical teams to deliver proactive, preventive care and can be adapted to each practice's protocols and standards.

1 investor

Longevity World is a wellness hub focused on helping individuals pursue longer, healthier lives through fitness, nutrition, and health innovation.

1 investor

The Longevity Biotechnology Association is a global non-profit organization that convenes longevity biotech companies, pharmaceuticals, researchers, and investors to establish industry standards and advance the translation of geroscience into therapeutic interventions that prevent age-related diseases and extend health span.

1 investor

Lucina Biotherapeutics develops therapeutics to treat aging-related disorders, particularly dry age-related macular degeneration (AMD), by restoring very long-chain polyunsaturated fatty acids (VLC-PUFAs) in tissues through its PUFActive platform. The company employs two approaches: synthetic VLC-PUFA formulations for intravitreal injection and engineered microorganism biofactories for oral delivery.

1 investor

Lumena Pharmaceuticals develops pharmaceutical, nutraceutical, and testing service products using biotechnology, with a focus on ethical practices in research, manufacturing, and distribution across health care markets. The company prioritizes environmental sustainability, reduced chemical use, and responsible innovation in bioavailable product development.

1 investor

Lura Care provides mobile, on-site health care services adapted for the elderly and people with functional diversity, delivered in care homes and day centres. Operating across Europe since 2015, it partners with over 1,000 centres to bring diagnosis and treatment to residents with mobility limitations.

1 investor

LyGenesis is a clinical-stage cell therapy company that uses a patient's own lymph nodes as bioreactors to grow functioning ectopic organs. Its allogeneic cell therapies target diseases including end stage liver disease, end stage renal disease, Type 1 diabetes, and aging of the thymus.

1 investor

LYMA develops wellness and beauty products including a nutritional supplement, an at-home laser device, and skincare, formulated with peer-reviewed, patented ingredients. The company sells directly to consumers seeking to improve how they look and feel.

1 investor

MaaT Pharma is a clinical-stage biotech developing microbiome-based therapeutics aimed at improving survival in cancer patients through immune modulation. It operates in the oncology and microbiome therapeutics space.

1 investor

A biotech company developing gene therapy treatments for neurodegenerative diseases. The company is led by a founder with extensive clinical and regulatory experience in cell and gene therapy, supported by advisors and board members with deep expertise in neurosurgery, clinical neuroscience, and gene therapy development.

1 investor

Groupe Maisons de Famille operates a network of more than 150 residential care facilities for frail elderly residents and patients, providing personalized care and support services. It is present in France, Italy, Spain, and Germany and describes itself as the fifth-largest such operator in Europe.

1 investor

Manna Tree Partners is a growth-stage venture capital firm that invests $25M-75M in companies across supply chain focus areas with connections to human health. The firm builds balanced, risk-adjusted portfolios with companies that have strong market positions and clear exit paths.

1 investor

Animate Biosciences develops peptide therapeutics that target pathological tissue remodeling, using an AI-powered platform that applies multi-omic data from highly regenerative organisms to design novel peptides. The company aims to treat conditions involving tissue and organ degeneration that currently have limited or no effective treatments.

1 investor

Megakaryon is a regenerative medicine company that develops cell therapies, including iPS cell-derived products such as platelets, for clinical applications. The company operates through collaborative research partnerships with academic institutions and pharmaceutical manufacturers in Japan and internationally.

1 investor

Mesenbio develops extracellular vesicle (EV) therapeutics derived from mesenchymal stem cells, using its FT-01 platform to enable scalable, GMP-ready EV manufacturing for regenerative medicine. The company is advancing a licensing-ready production platform and preclinical therapeutic candidate (MEV-N01) targeting rheumatoid arthritis.

1 investor

Mighty Therapeutics is a biopharmaceutical company developing mitochondria-targeted medicines to treat mitochondrial dysfunction in rare genetic mitochondrial diseases and common age-related conditions. Its pipeline spans rare genetic diseases, ophthalmic disorders, and neurological conditions, and it delivered the first approved therapy for Barth syndrome.

1 investor

MiiCare operates a chronic conditions management platform for in-home care, built around MiiCube, a home hub, and Monica, a voice-based conversational AI health assistant that monitors behavior, measures vitals, and supports care plans. It serves chronic care providers, home care, senior living, and post-acute care organizations, with a care manager dashboard for tracking patient health and prioritizing interventions.

1 investor

Guangzhou Yinming Biomedical Technology is a China-based company developing novel drugs in-house, with a pipeline spanning ophthalmic therapies, recombinant protein botulinum toxin, cancer immunotherapy, and pet immunology drugs. Its research is led by a team of scientists and its main candidates have reached the clinical stage.

1 investor

Minicircle develops non-viral plasmid gene therapy for consumer health and wellness, with its lead product aimed at supporting lean muscle, vitality, and lowering epigenetic age. The therapy is offered to individuals through health clinics in Central America.

1 investor

Miromatrix develops fully biologic organs using decellularization and recellularization technology for transplant patients. The company focuses on engineering transplantable kidneys, livers, and liver support devices to address the critical shortage of donor organs.

1 investor

Mitrix Bio develops bioreactor-grown young mitochondria encased in extracellular vesicles ("Mitlets") intended for transplantation to supplement aging cells. The company targets mitochondrial dysfunction implicated in age-related diseases such as Alzheimer's, retinal disease, liver dysfunction, and immune senescence.

1 investor